Adj. Clinical Professor of Endocrinology, Gerontology and Metabolism Stanford university School of Medicine Attending, Osteoporosis and Metabolic Bone Disease Clinic Stanford university Hospital and Clinics

Endocrinology

Dr. David B. Karpf practices Endocrinology. He graduated from University of California San Diego School of Medicine. University of California San Diego School of Medicine has a rank of 17 in research and a 19 in primary care He received awards:"NIH FIRST Award", "Merit Review Award, VAMC-SF", "Research Associate Award, VAMC-SF", "Merck, Sharp & Dohme Young Investigator Award", "Associate Investigator Award, VAMC-SF", "Magna cum Laude, UC Berkeley", "Presidential Fellowship, University of California, Berkeley", "UCLA High School Honors Program" and "National Merit Scholar". David B. Karpf is a published doctor and has 23 publications published. The lastest was: 'Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.'

Publications

---

• Effects of the PPAR-? agonist MBX-8025 on atherogenic dyslipidemia.
• MBX-8025, A Novel Peroxisome Proliferator Receptor-{delta} Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Ator...
• The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
• Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
• Blinded reading of radiographs increases the frequency of errors in vertebral fracture detection.
• Design of the Fracture Intervention Trial.
• Covalent labeling of a high-affinity, guanyl nucleotide sensitive parathyroid hormone receptor in canine renal cortex.
• Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
• Influence of age and sex on plasma calcitonin in human beings.
• Current concepts in acromegaly: etiology, diagnosis, and treatment.
• In vitro secretion of deoxycorticosterone by a benign Leydig cell tumor of the testis.
• Structural properties of the renal parathyroid hormone receptor: hydrodynamic analysis and protease sensitivity.
• The canine renal parathyroid hormone receptor is a glycoprotein: characterization and partial purification.
• Features of the renal parathyroid hormone-parathyroid hormone-related protein receptor derived from structural studies of receptor fragments.
• Two homologs of the Drosophila polarity gene frizzled (fz) are widely expressed in mammalian tissues.
• CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.
• Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
• Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
• Injury prevention.
• Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
• The effects of alendronate on stature and the spine deformity index.

Schools

---

• University Of California San Diego School Of Medicine

• Cedars Sinai Med Center

• UCLACedars Sinai

• UcsfVa Med Center

Doctors Specialties

---

• Internal Medicine
• Endocrinology

Accepted Insurances

---

• Aetna HMO
• Choice Plus POS II
• Blue Card PPO
• Advantage Preferred DirectAccess Plus PPO
• Blue Cross Blue Shield of California PPO
• Select PPO
• Access Plus Savenet
• Basic Exclusive PPO for Small Business
• Basic PPO
• Cigna HMO
• Commercial Insurance Company
• First Health (Coventry Health Care) PPO
• Medicare Advantage PFFS
• Medicare MCR
• Kaiser PHCS Network PPO
• MultiPlan PPO
• PHCS Network PPO
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO
• PacifiCare HMO
• United Healthcare

Awards

---

• NIH FIRST Award
• Merit Review Award, VAMC-SF
• Research Associate Award, VAMC-SF
• Merck, Sharp & Dohme Young Investigator Award
• Associate Investigator Award, VAMC-SF
• Magna cum Laude, UC Berkeley
• Presidential Fellowship, University of California, Berkeley
• UCLA High School Honors Program
• National Merit Scholar

Education

---

• Cedars-Sinai Medical Center
• UCLA Affiliated Hospitals
• University of California San Diego School of Medicine

Hospital

---

• Stanford Health Care

Drug Facts

---

NPI NUMBER		1306913744
NPPES Provider LastName		KARPF
NPPES Provider FirstName		DAVID
NPPES Provider ZIPCode		943052200
NPPES Provider State		CA
Specialty Description		Endocrinology
Total Claim Count		40.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1306913744
Last Name Of The Provider	KARPF
First Name Of The Provider	DAVID
View All

Similar Doctors

---

	Dr. Christian S. Eversull, MD This Doctor is OpenDoctor Recommended.
	Dr. Phyllis I. Gardner, MD This Doctor is OpenDoctor Recommended.
	Dr. Marianne K. Yeung, MD
	Dr. Stephen P. Fortmann, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Fahim Abbasi, MD This Doctor is OpenDoctor Recommended.
	Dr. Aimee D. Shu, MD This Doctor is OpenDoctor Recommended.
	Dr. Marilyn Tan, MD This Doctor is OpenDoctor Recommended.
	Dr. Fredric B. Kraemer, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Peter M. Sklarin, MD This Doctor is OpenDoctor Recommended.
	Dr. Tracey McLaughlin, MD This Doctor is OpenDoctor Recommended.
	Dr. Joy Y. Wu, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog